07:37 AM EDT, 10/09/2024 (MT Newswires) -- Kymera Therapeutics ( KYMR ) said Wednesday that the US Food and Drug Administration has cleared its investigational new-drug application for KT-621, a potential treatment for patients with atopic and allergic diseases.

The biotech company said it expects to initiate dosing in an early-stage clinical trial in healthy volunteers this month and report data from the study in H1 of next year. The trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of KT-621 compared to placebo.